

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

April 01, 2015

LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Salix Pharmaceuticals, Ltd. Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN[®] (rifaximin) 550 mg, RUCONEST[®] (C1 esterase inhibitor [recombinant]), APRISO[®] (mesalamine), UCERIS[®] (budesonide) extended release tablets and RELISTOR[®] (methylnaltrexone bromide).

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

www.valeant.com

.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Media:
Renee E. Soto / Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com
/
mgavigan@sardverb.com

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-completes-acquisition-of-salix-pharmaceuticals-300059279.html>

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

ir@bauschhealth.com



LEGAL NOTICE

PRIVACY POLICY

877-281-6642
514-856-3855 (Canada)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

Use of this site signifies your agreement to
the [Legal Notice and Privacy Policy](#).

©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**

